GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (LTS:0QW0) » Definitions » Beginning Cash Position

argenx SE (LTS:0QW0) Beginning Cash Position : €0 Mil (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is argenx SE Beginning Cash Position?

argenx SE's Beginning Cash Position for the quarter that ended in Mar. 2025 was €0 Mil.

argenx SE's annual Beginning Cash Position declined from Dec. 2022 (€1,260 Mil) to Dec. 2023 (€734 Mil) but then increased from Dec. 2023 (€734 Mil) to Dec. 2024 (€1,957 Mil).

argenx SE Beginning Cash Position Historical Data

The historical data trend for argenx SE's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Beginning Cash Position Chart

argenx SE Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 305.92 1,076.87 1,259.94 734.28 1,956.65

argenx SE Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

argenx SE Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

argenx SE Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of argenx SE's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (LTS:0QW0) » Definitions » Beginning Cash Position
Comparable Companies
XBRU:UCB XBRU:TUB XBRU:ONWD XBRU:HYL XBRU:ALEMS XBRU:BIOS XBRU:OXUR VRTX ASX:CSL REGN XKRX:207940 ALNY ONC XKRX:068270 BNTX SMMT RPRX OCSE:GMAB XKRX:196170 INCY
Traded in Other Exchanges
ARGX:USA ARGXb:UK 1AEA:Germany 1AE:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria
Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Website
https://www.argenx.com
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

argenx SE Headlines

No Headlines